

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1.-57. (Canceled)

58. (Previously presented) A method of reducing inflammation in a subject having an inflammatory disease comprising administering to the subject a therapeutically effective amount of a composition comprising a fusion protein comprising:

- (a) amino acid sequence comprising amino acid 42 to amino acid 60 of SEQ ID NO:2, and
- (b) a non-P selectin ligand amino acid sequence.

59. (Previously presented) The method of claim 58, wherein said inflammatory disease is chosen from arthritis, gout, uveitis, acute respiratory distress syndrome, asthma, emphysema, delayed type hypersensitivity reaction, systemic lupus erythematosus, thermal burns, frostbite, autoimmune thyroiditis, experimental allergic encephalomyelitis, multiple sclerosis, multiple organ injury syndrome secondary to trauma, diabetes, Reynaud's syndrome, neutrophilic dermatosis, inflammatory bowel disease, Grave's disease, glomerulonephritis, gingivitis, periodontitis, hemolytic uremic syndrome, ulcerative colitis, Crohn's disease, necrotizing enterocolitis, granulocyte transfusion associated syndrome, and cytokine induced toxicity.

60. (Previously presented) A method of reducing inflammation in a subject by inhibiting selectin-mediated intercellular adhesion in the subject comprising

administering to the subject a therapeutically effective amount of a fusion protein comprising:

(a) an amino acid sequence comprising amino acid 42 to amino acid 60 of SEQ ID NO:2, and

(b) a non-P selectin ligand amino acid sequence.

61. (Previously presented) The method of claim 60, wherein the subject has a condition chosen from myocardial infarction, bacterial infection, viral infection, metastasis, thrombotic disorder, parasitic disease, organ transplant rejection, arthritis, gout, uveitis, acute respiratory distress syndrome, asthma, emphysema, delayed type hypersensitivity reaction, systemic lupus erythematosus, thermal burns, frostbite, autoimmune thyroiditis, experimental allergic encephalomyelitis, multiple sclerosis, multiple organ injury syndrome secondary to trauma, diabetes, Reynaud's syndrome, neutrophilic dermatosis, inflammatory bowel disease, Grave's disease, glomerulonephritis, gingivitis, periodontitis, hemolytic uremic syndrome, ulcerative colitis, Crohn's disease, necrotizing enterocolitis, granulocyte transfusion associated syndrome, and cytokine induced toxicity.

62. (Previously presented) The method of claim 60, wherein the subject is a hemodialysis or leukapheresis patient.

63. (Previously presented) A method of reducing inflammation in a subject having a condition characterized by selectin-mediated intercellular adhesion, comprising administering a therapeutically effective amount of a soluble P-selectin ligand protein, or a fragment thereof having P-selectin ligand activity, wherein the soluble P-selectin ligand protein or fragment comprises amino acid 42 to amino acid 60 of SEQ ID NO:2.

64. (Previously presented) The method of claim 63, wherein the P-selectin ligand protein or fragment comprises amino acid 42 to amino acid 88 of SEQ ID NO:2; amino acid 42 to amino acid 118 of SEQ ID NO:2; amino acid 42 to amino acid 189 of SEQ ID NO:2; amino acid 42 to amino acid 310 of SEQ ID NO:2; or amino acid 42 to amino acid 402 of SEQ ID NO:2.

65. (Previously presented) The method of claim 63, wherein the soluble P-selectin ligand protein, or a fragment thereof having P-selectin ligand activity, further comprises an Fc portion of an immunoglobulin.

66. (Previously presented) The method of claim 65, wherein the immunoglobulin is IgG.

67. (Previously presented) The method of claim 63, wherein the condition is chosen from myocardial infarction, bacterial infection, viral infection, metastasis, thrombotic disorder, parasitic disease, organ transplant rejection, hemodialysis, leukophoresis, arthritis, gout, uveitis, acute respiratory distress syndrome, asthma, emphysema, delayed type hypersensitivity reaction, systemic lupus erythematosus, thermal burns, frostbite, autoimmune thyroiditis, experimental allergic encephalomyelitis, multiple sclerosis, multiple organ injury syndrome secondary to trauma, diabetes, Reynaud's syndrome, neutrophilic dermatosis, inflammatory bowel disease, Grave's disease, glomerulonephritis, gingivitis, periodontitis, hemolytic uremic syndrome, ulcerative colitis, Crohn's disease, necrotizing enterocolitis, granulocyte transfusion associated syndrome, and cytokine induced toxicity.

68. (Previously presented) A method of reducing inflammation in a subject having myocardial infarction comprising administering to the subject a therapeutically

effective amount of a composition comprising a soluble P-selectin ligand protein comprising amino acid 42 to amino acid 88 of SEQ ID NO:2.

69. (Previously presented) A method of reducing inflammation in a subject having a thrombotic disorder comprising administering to the subject a therapeutically effective amount of a composition comprising soluble P-selectin ligand protein comprising amino acid 42 to amino acid 88 of SEQ ID NO:2.

70. (Previously presented) The method of claim 58, wherein the inflammatory disease is multiple sclerosis.

71. (Previously presented) The method of claim 63, wherein the subject has multiple sclerosis.